Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection.
about
P1343
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanomaTumor antigens and tumor vaccines: peptides as immunogens.Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.An overview of cancer immunotherapy.Immune selection in neoplasia: towards a microevolutionary model of cancer development.A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.Identifying source proteins for MHC class I-presented peptides.tLivin displays flexibility by promoting alternative cell death mechanismsStrengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.Irradiation of donor mononuclear cells for treatment of chemorefractory metastatic solid cancers: a community-based immune transplant pilot studyMultiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapyIdentification of T-cell epitopes for cancer immunotherapy.Design and development of synthetic peptide vaccines: past, present and future.Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.HLA associations in the antitumor response against malignant melanoma.Role of gene methylation in antitumor immune response: implication for tumor progression.Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.Lessons from cancer immunoediting in cutaneous melanoma.Modulating the innate immune activity in murine tumor microenvironment by a combination of inducer molecules attached to microparticles.MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma.Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor.Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation.HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity.Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.Gene therapy for cancer: what have we done and where are we going?The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles.
P2860
Q24307739-0277B516-048A-4223-A8FF-41D8D9DA5ECBQ30469630-81CC9624-E528-467A-AEF8-BD2A8AF25570Q30565493-E27D60A0-39BE-4A9D-A79E-29D2E2AC12F5Q33499949-673B4E7A-612E-490C-8A95-0A4274F5262CQ33501195-9CF5A3AC-0C33-47C9-9404-67D4D628DC3FQ33940388-503CCCB6-6B04-49D1-965D-470AA2688442Q33948688-9A5A3CB1-CACF-45A3-B774-30341C8B112DQ34021153-3A173E73-52F8-4FFB-93E8-B5FB9B7BDAE0Q34452013-A6A287E9-9C5C-472A-A201-636A0DD4A00AQ34553385-105B881F-718C-4DE3-A58D-0D17388ED3C4Q35194005-D60269B9-AFCE-48B1-A099-AD342AD1074AQ35209044-B026C0E3-D808-4921-B657-0A9F8930E6A9Q35946213-91D876A5-0930-4398-9C92-919FF153FC38Q36089567-1E4872B4-4B61-4E2A-9ED2-B9306106F26EQ36283696-2A4A6C48-7804-4753-8A7A-C8BDC8E876C0Q36365751-6EEEA829-E733-47F4-81DF-6E717567660BQ36365932-38B7C46D-0F26-4FFE-9C51-3D47E6ED01C5Q36367205-2F00E890-1562-43EC-9A49-119EB27D9B89Q36367223-71D2EAEE-09F6-4239-9DC3-343F17145869Q36375095-7965763B-721C-440D-A696-1C47F8FF3CD0Q36431817-95027B06-FE7F-468A-B919-61583FA9A58DQ36719911-57DAC85B-CB95-41E7-BBD3-AB4D583341EAQ36870592-36B57B7B-E186-42F5-88EE-15BB8A487426Q36899093-50A5ECC0-6851-470F-A9EE-7DFBB478C2A8Q36914397-AA10DA16-8BD0-4CA9-8D2F-35576CEF10A3Q36924466-F51FDF1A-5A51-4E6E-9240-AA0717791322Q37132658-9EE2CFDB-EE09-4A4A-81E3-888925F7EC48Q37360526-A33C009E-01DE-4D2F-974A-F1D5498A5806Q37383437-C3A18ADB-416F-48E5-83C6-3324A0C95FA0Q38038176-41F8D6E8-68B7-4296-B33F-EC1A5DE9EBECQ38868855-D73FF8D3-373A-4E34-883A-383750D65468Q38885288-9A91E2AD-6FB2-4A06-8EA1-1282A3682567Q39322560-1FBFCA6B-B6F3-410F-9285-DC878721934AQ39429911-78DC7E45-8C78-48B4-BC9C-99731ADC8CC7Q39767619-E27E7722-C5D2-4CAB-BC85-BB3698D03819Q40639521-CD13FCC9-DEC4-4284-B9A3-673FC83B3DA1Q40734971-6B562723-E84B-44DC-B5DA-7B1F40743AD3Q40823586-EF67E64E-4D2F-462D-B783-400502931F6AQ40916302-953EC132-0FA8-49BD-8B35-F7DC769A04E7Q41013301-07BB0E1A-D37E-45E8-80B4-1E252DE478A6
P2860
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Differences in the antigens re ...... sistent with immune selection.
@en
type
label
Differences in the antigens re ...... sistent with immune selection.
@en
prefLabel
Differences in the antigens re ...... sistent with immune selection.
@en
P2093
P356
P1476
Differences in the antigens re ...... sistent with immune selection.
@en
P2093
Marchand M
Pouillart P
P2860
P304
P356
10.1002/EJI.1830250206
P407
P4510
P577
1995-02-01T00:00:00Z